Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
188 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Lexicon Pharmaceuticals, Inc.’s names, not what it holds today.
Patents granted
188
188 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against none in 2024 and 2 in 2023
Applications published
74
7 of them in 2025
Names they are printed under
3
a former name, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
Organic fine chemistry2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Lexicon Genetics, Inc. a former name
US, as the owner printed on each patent
17 publishedLEXICON PHARMACEUTICALS, INC. its own name
US, as the owner printed on each patent
27 publishedLexicon Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
30 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jul 1, 2025 | 12,344,596 | Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| May 27, 2025 | 12,312,325 | Methods and compounds useful in the synthesis of an AAK1 inhibitor | Organic fine chemistry | LEXICON PHARMACEUTICALS, INC. |
| Aug 22, 2023 | 11,730,723 | Compounds and methods for treating viral infections | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| Jun 6, 2023 | 11,666,575 | Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| Jul 13, 2021 | 11,059,907 | Antibodies that bind Notum Pectinacetylesterase | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| Apr 6, 2021 | 10,968,192 | Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis | Organic fine chemistry | LEXICON PHARMACEUTICALS, INC. |
| Oct 23, 2018 | 10,106,569 | Inhibitors of sodium glucose transporter 1 for constipation | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| Jan 9, 2018 | 9,862,724 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| Jun 27, 2017 | 9,688,710 | Inhibitors of sodium glucose cotransporter 1 | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| Jun 20, 2017 | 9,682,982 | Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 13, 2025 | 2025/0346570 | SOLID FORMS OF (S)-1-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE AND METHODS OF THEIR USE | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| Sep 11, 2025 | 2025/0282747 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | Organic fine chemistry | LEXICON PHARMACEUTICALS, INC. |
| Sep 4, 2025 | 2025/0275959 | COMPOUNDS AND METHODS OF THEIR USE | Organic fine chemistry | Lexicon Pharmaceuticals, Inc. |
| Aug 21, 2025 | 2025/0262197 | COMPOUNDS AND METHODS FOR TREATING CHEMOTHERAPY-INDUCED PAIN | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| May 29, 2025 | 2025/0170157 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | Pharmaceuticals | Lexicon Pharmaceuticals, Inc. |
| Apr 10, 2025 | 2025/0114323 | METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| Apr 3, 2025 | 2025/0108032 | METHODS OF TREATING TYPE 1 DIABETES AND KIDNEY DISEASE | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| Jul 11, 2024 | 2024/0226125 | USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES MELLITUS | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| Mar 28, 2024 | 2024/0100013 | SOTAGLIFLOZIN FOR IMPROVING LEFT ATRIAL FUNCTION | Pharmaceuticals | LEXICON PHARMACEUTICALS, INC. |
| Nov 9, 2023 | 2023/0357182 | SOLID FORMS OF (S)-1-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE AND SALTS THEREOF | Pharmaceuticals | Lexicon Pharmaceuticals, Inc. · patent 12,344,596 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Organic fine chemistry 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.